Scorpius Holdings, Inc.

NYSEAM:SCPX Stok Raporu

Piyasa değeri: US$2.2m

Scorpius Holdings Temettü

Temettü kriter kontrolleri 0/6

Scorpius Holdings does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-354.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi-354.0%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics names Anthony Manning as chief scientific advisor

May 10

Heat Biologics EPS misses by $0.01, misses on revenue

May 05

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Apr 30
We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07
Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if SCPX's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if SCPX's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

Scorpius Holdings Piyasaya Karşı Temettü Getirisi
SCPX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (SCPX)n/a
Pazarın Alt %25'i (US)1.5%
Pazarın En İyi %25'i (US)4.5%
Sektör Ortalaması (Biotechs)2.2%
Analist tahmini (SCPX) (3 yıla kadar)n/a

Önemli Temettü: Unable to evaluate SCPX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate SCPX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate SCPX's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as SCPX has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin